Solu Therapeutics Appoints Michael Boretti, Ph.D., as Chief Business Officer

MEDFORD, Mass.–(BUSINESS WIRE)–Solu Therapeutics, a biotechnology company focused on developing therapeutics to eliminate disease-driving cells using its CyTaC^TM (Cytotoxicity Targeting Chimera) platform, today announced the appointment of Michael I. Boretti, Ph.D., as Chief Business Officer (CBO).

Dr. Boretti brings over 15 years of biotechnology leadership experience to Solu, including an extensive track record of company-building and deal-making across diverse therapeutic indications. As CBO, he will lead Solu’s business development strategy, strategic financing and alliance management activities.

“Solu’s innovative approach to unlocking previously inaccessible targets with the CyTaC platform presents a new modality to efficiently remove the cells that drive disease across a wide range of indications,” commented Dr. Boretti. “I am excited to become a part of the passionate Solu team to advance the development of novel medicines to positively impact patients’ lives.”

Dr. Boretti was most recently the CBO of Celsius Therapeutics, where he was responsible for business development and other operations. His previous strategic biopharma leadership positions include Vice President of Business Development at Epizyme and Vice President of Corporate Development and Alliance Management at Aveo Oncology. Dr. Boretti began his career in life science consulting at L.E.K. after he received his Ph.D. in Bioengineering from the University of Pennsylvania.

“We are delighted to welcome Mike to Solu’s executive team. His ability to drive strategic collaborations and financing activities will be an asset during this pivotal period of growth as we continue to develop the CyTaC platform and advance a pipeline of next-generation medicines to treat oncology and immune-mediated diseases,” said Philip J. Vickers, Ph.D., President and Chief Executive Officer, Solu Therapeutics. “As an accomplished, collaborative corporate strategist, Mike is an ideal addition to the Solu leadership team as we work to maximize the value and impact of our platform.”

About Solu Therapeutics

Solu Therapeutics is a biotechnology company focused on developing therapeutics to eliminate disease-driving cells in cancer and immunology. The proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates, exclusively licensed from GSK, unlocks cell surface targets including GPCRs and ion channels that are difficult to target via traditional biologic and small molecule approaches. The CyTaC platform provides the capability to develop next generation medicines that harness the power of biologics with the vast target binding space of small molecules.

Contacts

Media
Karen Sharma

MacDougall Advisors

[email protected]